王四坤,胡晓军.普罗布考对冠心病合并糖尿病患者PCI术后对比剂肾病的影响[J].内科急危重症杂志,2015,21(21):
扫码阅读全文
|
| DOI： |
| 中文关键词: 普罗布考 经皮冠状动脉介入术 对比剂肾病 |
| 英文关键词:Probucol percutaneous coronary intervention contrast-induced nephropathy |
| 基金项目: |
|
| 摘要点击次数: 3088 |
| 全文下载次数: 3758 |
| 中文摘要: |
| 【】目的：观察普罗布考对冠心病合并糖尿病患者PCI术后对比剂肾病(CIN)的预防作用,探索其可能机制。方法：将90例择期行PCI合并糖尿病的冠心病患者随机分为治疗组及对照组。治疗组在常规治疗基础上,于术前3-5天开始服用普罗布考,0.5/次,2次/日。测患者入院时及术后24h、48h、72h血肌酐(SCr)和胱抑素C(CysC)水平,检测患者术前及术后3天超敏C反应蛋白(hsCRP)、脂质过氧化物(MDA)、一氧化氮(NO)、内皮素-1(ET-1)浓度变化。结果：普罗布考组CIN发生率(6. 5%)显著低于对照组(15. 9%,P < 0.05);普罗布考组术后3天hsCRP、MDA及ET-1水平低于对照组(P < 0.05),而术后3天血浆NO水平高于对照组(P < 0.05)。结论：普罗布考能抑制PCI术后炎症反应,减轻脂质过氧化损伤,改善内皮功能,预防CIN发生。 |
| 英文摘要: |
| 【】 Objective To investigate the effects of Probucol on contrast-induced nephropathy(CIN) after percutaneous coronary intervention(PCI)in patients with type 2 diabetes and its impossible mechanism. Methods A total of ninety patients with diabetes admitted for elective PCI were randomly divided into the therapy group(n=46) and control group(n=44)．All patients were treated with conventional medicine. Accessory to the conventional medicine,the therapy group was administered with 500mg Bid probucol 3-5 days PCI preoperatively. Serum creatinine ( SCr ) and CystatinC ( CysC) concentrations were measured at admission,24 hours,48 hours and 72 hours after PCI. Serum hsCRP,malondialdehyde(MDA) ,NO and ET-1 levels were determined immediately before operation,3 d after operation．Results The incidences of CIN was 6. 5%( 3 /46) and 15. 9% ( 7 /44) in therapy and control group respectively and the incidence of CIN in therapy group was lower than that in control group ( P ＜ 0. 05) . The levels of hsCRP,MDA and ET-1 in therapy group were lower than those in control group at 3d after operation,while the level of NO was higher than that in control group( P ＜ 0. 05). Conclusion Probucol may antioxidize, inhibit inflammation and improve endothelial function after PCI in coronary heart disease patients with type 2 diabetes to prevent the contrast-induced nephropathy. |
|
|
|
|
